Yanbing Li
Clinical trials sponsored by Yanbing Li, explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New study aims to find best Long-Term insulin plan after intensive therapy for type 2 diabetes Results expected Jun 2027 (estimated)
- New biweekly diabetes pill could replace daily dosing Results expected Jul 2027 (estimated)
-
Can a weekly shot reverse type 2 diabetes?
Disease control Not yet recruitingThis trial tests whether mazdutide, a weekly injection, can help people with type 2 diabetes achieve normal blood sugar levels—a state called remission. Participants are adults with type 2 diabetes who are not well controlled on diet, exercise, or a single medication. They receiv…
Sponsor: Yanbing Li • Aim: Disease control
Last updated Aug 19, 2026 00:00 UTC
-
New study aims to find best Long-Term insulin plan after intensive therapy for type 2 diabetes
Disease control Not yet recruitingThis study enrolls 324 adults with type 2 diabetes whose blood sugar is not well controlled on oral medications. All participants will first receive short-term intensive insulin therapy in the hospital. Then, they will be randomly assigned to one of three insulin-based regimens f…
Phase 4 • Sponsor: Yanbing Li • Aim: Disease control
Last updated Jun 27, 2026 09:03 UTC
-
New biweekly diabetes pill could replace daily dosing
Disease control Not yet recruitingThis study will compare two diabetes medications, cofrogliptin and linagliptin, when added to insulin therapy in Chinese adults with type 2 diabetes. About 594 participants will take either a biweekly or daily pill alongside their usual insulin. Researchers will track blood sugar…
Sponsor: Yanbing Li • Aim: Disease control
Last updated Jun 27, 2026 07:52 UTC